Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

INMB Relative to the S&P 500

INMB Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the INmune Bio Inc. (NASD:INMB) seasonal charts above shows that a Buy Date of November 23 and a Sell Date of February 14 has resulted in a geometric average return of 42.82% above the benchmark rate of the S&P 500 Total Return Index over the past 6 years. This seasonal timeframe has shown positive results compared to the benchmark in 5 of those periods. This is a very good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 6 years by an average of 72.73% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

A word of caution: Only 6 years of data is available for shares of INMB, perhaps insufficient to create a seasonal profile that accurately gauges the seasonal tendencies influencing the investment. Ideally, while 20 years is preferred, at least 10 years of data is required to perform a seasonal analysis that is considered to be reliable for future seasonal periods.

INmune Bio, Inc. is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprogram the immune system to fight cancer and Alzheimer s disease. Its product pipeline includes INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell on September 25, 2015 and is headquartered in Boca Raton, FL.

To download INMB seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: INMB